n.a. (FURX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 10.82M
Div & Yield N.A. (N.A)
Furiex Pharmaceuticals Announces Acceptance To Late-Breaking Abstract Session At Digestive Disease Week 2014

Furiex Pharmaceuticals Announces Acceptance To Late-Breaking Abstract Session At Digestive Disease Week 2014

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that results from its two Phase III clinical trials of eluxadoline in patients with diarrhea-predominant irritable bowel syndrome will be presented in a ...

Furiex Pharmaceuticals Confirms Takeda Will Present Additional Data From The EXAMINE Trial At The American College Of Cardiology’s 63rd Annual Scientific Session

Furiex Pharmaceuticals Confirms Takeda Will Present Additional Data From The EXAMINE Trial At The American College Of Cardiology’s 63rd Annual Scientific Session

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that its partner Takeda Pharmaceuticals Company Limited (Takeda) will present sub-analyses from the global EXAMINE ( EXamination of C Ardiovascular Outco Mes:...

Trade-Ideas: Furiex Pharmaceuticals (FURX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Furiex Pharmaceuticals (FURX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Furiex Pharmaceuticals (FURX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Furiex Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results

Furiex Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2013.

Furiex Pharmaceuticals Confirms Takeda’s Submission Of A New Drug Application For Trelagliptin Succinate (SYR-472) In Japan For The Treatment Of Type 2 Diabetes

Furiex Pharmaceuticals Confirms Takeda’s Submission Of A New Drug Application For Trelagliptin Succinate (SYR-472) In Japan For The Treatment Of Type 2 Diabetes

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that it has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare...

Furiex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Fourth Quarter 2013 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its fourth quarter 2013 financial results on Tuesday, March 11, 2014, after the market closes.

Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta

Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

3 Stocks Breaking Out on Unusual Volume

3 Stocks Breaking Out on Unusual Volume

These stocks trading on unusual volume are within range of triggering breakout trades.

Furiex Pharmaceuticals (FURX) Showing Signs Of Perilous Reversal Today

Furiex Pharmaceuticals (FURX) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Furiex Pharmaceuticals (FURX) as a "perilous reversal" (up big yesterday but down big today) candidate

Jim Cramer's 6 Stocks in 60 Seconds: DIS PFE AAPL SBUX TTWO FURX (Update 1)

Jim Cramer's 6 Stocks in 60 Seconds: DIS PFE AAPL SBUX TTWO FURX (Update 1)

Cramer likes the call on Disney, sees good things happening for Pfizer but is staying away from Furiex Pharmaceuticals.

Furiex Pharma Diarrhea Drug Produces Solid Results in Pivotal Studies

Furiex Pharma Diarrhea Drug Produces Solid Results in Pivotal Studies

An FDA approval filing for Furiex's eluxadoline will be submitted in the second quarter.

Today's Pre-Market Mover With Heavy Volume: Furiex Pharmaceuticals (FURX)

Today's Pre-Market Mover With Heavy Volume: Furiex Pharmaceuticals (FURX)

Trade-Ideas LLC identified Furiex Pharmaceuticals (FURX) as a pre-market mover with heavy volume candidate

Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d

Furiex Pharmaceuticals Announces Positive Top-Line Results Of Two Pivotal Phase III Clinical Trials Of Eluxadoline In Patients With IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced top-line results indicating the company’s two pivotal Phase III clinical trials evaluating the efficacy and safety of eluxadoline in the treatment of ...

Furiex Reports Third Quarter 2013 Financial Results

Furiex Reports Third Quarter 2013 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

Furiex Pharmaceuticals Announces Priligy® Launch In The United Kingdom By Menarini

Furiex Pharmaceuticals Announces Priligy® Launch In The United Kingdom By Menarini

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX), a drug development collaboration company, today announced it will receive a $5.

Furiex Pharmaceuticals Announces Management Changes

Furiex Pharmaceuticals Announces Management Changes

Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) announced today the appointment of Sailash Patel to the position of Chief Financial Officer, effective November 15, 2013.

Furiex Pharmaceuticals Announces Third Quarter 2013 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Third Quarter 2013 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its third quarter 2013 financial results on Tuesday, November 5, 2013, after the market closes.

Furiex Pharmaceuticals Enters Into A Loan Agreement For $15 Million And Restructures Its Existing Secured Loan

Furiex Pharmaceuticals Enters Into A Loan Agreement For $15 Million And Restructures Its Existing Secured Loan

Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) announced today it has executed a $15 million debt financing transaction with Fred Eshelman, Pharm.

Furiex Confirms Takeda Receives European Marketing Authorization For VIPIDIA™ (alogliptin), VIPDOMET™ (alogliptin And Metformin) And INCRESYNC™ (alogliptin And Pioglitazone)

Furiex Confirms Takeda Receives European Marketing Authorization For VIPIDIA™ (alogliptin), VIPDOMET™ (alogliptin And Metformin) And INCRESYNC™ (alogliptin And Pioglitazone)

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed Takeda Pharmaceutical Company Limited (Takeda)’s announcement that the European Commission has granted Marketing Authorization (MA) for VIPIDIA™ ...

Furiex Confirms Alogliptin Cardiovascular Safety Outcomes Trial (EXAMINE) Met Primary Endpoint

Furiex Confirms Alogliptin Cardiovascular Safety Outcomes Trial (EXAMINE) Met Primary Endpoint

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited (Takeda) announced top line results of the EXAMINE ( EXamination of C Ardiovascular Outco Mes: Aloglipt IN vs.

Furiex Reports Second Quarter 2013 Financial Results

Furiex Reports Second Quarter 2013 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended June 30, 2013.

Furiex Confirms Takeda Receives Positive CHMP Opinion For VIPIDIA™ (alogliptin) And Fixed-Dose Combinations VIPDOMET™ (alogliptin And Metformin) And INCRESYNC™ (alogliptin And Pioglitazone)

Furiex Confirms Takeda Receives Positive CHMP Opinion For VIPIDIA™ (alogliptin) And Fixed-Dose Combinations VIPDOMET™ (alogliptin And Metformin) And INCRESYNC™ (alogliptin And Pioglitazone)

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited (Takeda) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Commit To Buy Furiex Pharmaceuticals At $45, Earn 14.7% Annualized

Commit To Buy Furiex Pharmaceuticals At $45, Earn 14.7% Annualized

Investors considering a purchase of Furiex Pharmaceuticals Inc stock, but tentative about paying the going market price of $49.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2014 put at the $45 strike, which has a bid at the time of this writing of $3.20.

4 Unusual-Volume Stocks to Watch

4 Unusual-Volume Stocks to Watch

Keep these stocks rising on unusual volume on your radar.

Furiex Pharmaceuticals Announces Completion Of Patient Enrollment For Its Phase III Clinical Trials Of Eluxadoline For IBS-d

Furiex Pharmaceuticals Announces Completion Of Patient Enrollment For Its Phase III Clinical Trials Of Eluxadoline For IBS-d

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced completion of patient enrollment in the company’s two ongoing Phase III clinical trials studying eluxadoline for the treatment of diarrhea-predominant ...

Furiex Pharmaceuticals Announces Second Quarter 2013 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Second Quarter 2013 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its second quarter 2013 financial results on Tuesday, August 6, 2013, after the market closes.

Ratings Moves: BYD, DLB, UPS

Ratings Moves: BYD, DLB, UPS

Boyd Gaming, Dolby and United Parcel Service get upgraded by TheStreet Quant Ratings. Brittany Umar details today's ratings changes.

Furiex Pharmaceuticals Inc. Stock Downgraded (FURX)

Furiex Pharmaceuticals Inc. Stock Downgraded (FURX)

Furiex Pharmaceuticals (Nasdaq:FURX) has been downgraded by TheStreet Ratings from from a hold to sell.

Ratings Changes To Be Publicly Issued on 5/30/13

Upgrades: ACM, ATEC, BYD, DLB, EJ, GGS, ITI, KTOS, PERY, RTIX, UPS, ZEP Downgrades: ASFI, DLLR, FURX, GLPW, GNMK, NPK, PESI, SPSC, XNY Initiations: ACRE, EDG, FRGI Read on to get TheStreet Quant Ratings' detailed report:

Furiex Reports Fourth Quarter And Full Year 2012 Financial Results

Furiex Reports Fourth Quarter And Full Year 2012 Financial Results

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2012.